|
The study by Winblad et al comparing
donepezil to placebo in severe Alzheimer’s disease (AD)
is important in establishing efficacy using outcomes appropriate
to this stage of disease. This study was made possible by Dr.
Winblad’s determination that patients with severe AD should
get as much attention as patients with mild cognitive impairment
(MCI) or early stages of AD. Similarly, Dr. Rockwood’s
determination in developing a patient and family-oriented outcome
measure has led to the publication of the study comparing galantamine
to placebo in mild to moderate AD using the Goal Attainment
Scaling (Rockwood et al).
Donepezil in patients with severe
Alzheimer’s disease:
double-blind, parallel-group, placebo-controlled study
(lancet 2006; 367:1057-1065)
BENGT WINBLAD,
LENA KILANDER,
STURE ERIKSSON,
LENNART MINTHON,
ET AL,
FOR THE SEVERE ALZHEIMER’S
DISEASE STUDY GROUP
various centres, SWEDEN
Attainment of treatment goals by
people with Alzheimer's disease receiving galantamine: a randomized
controlled trial
(CMAJ 2006;174(8):1099-1105)
KENNETH ROCKWOOD,
SHERRI FAY,
xIAOWEI SONG,
CHRIS MACKNIGHT,
ET AL,
on behalf of the
video-imagi ng synthesis
of treati ng alzheimer's
disease (vista ) Investigators ,
various centres, canada
|
